A Tailored Approach to Non-Melanoma Skin Cancers: Managing the High-Risk Patient With Systemic Immune-Activating Therapy

2025
ACMS
CSCC
BCC
CME
At the 2025 ACMS meeting Drs. Miller and Patel discuss pearls in managing the high-risk patient with systemic immune-activating therapy
Authors

David M. Miller

Vishal A. Patel

Published

May 16, 2025

Event

American College of Mohs Surgery 2025 at the Gaylord Opryland Resort & Convention Center

Overview & Learning Objectives

  • Explain the risk assessment of patients with non-melanoma skin cancers (NMSCs) who may derive optimal benefit with new systemic therapies when compared with Mohs surgery
  • Incorporate patient trials data for systemic immunotherapy into the treatment of both advanced cutaneous squamous cell carcinoma and basal cell carcinoma
  • Collaborate with other members of the NMSC healthcare team to provide a multidisciplinary approach to the development of treatment plans for individuals with high-risk NMSCs
This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement